Daclizumab was a self-administered injection, given under the skin once a month to treat RRMS.
In two clinical trials, Daclizumab was shown to reduce relapses by 50% compared to placebo, and 46% versus Beta-Interferon. Those taking the drug had fewer, smaller or no new lesions on MRI. In one study it was also shown to reduce disability progression by 50%, although this was not reproduced in the second trial.
Common side effects included skin rash, depression, flu-like symptoms, respiratory and urinary tract infections, inflammation of the bowel and potentially severe liver damage.
Initially this limited Daclizumab’s use to those who had already tried two other DMDs, or who had exhausted other options. It was not to be used in pwMS with pre-existing liver disease.
In March 2018 however, reports of 7 cases of previously unrecognised inflammatory brain disorders (encephalitis and meningoencephalitis) led to the manufacturer voluntarily removing the drug from the worldwide market and to stop ongoing clinical trials.
Page last updated 11 April 2019
- Daclizumab withdrawn from the market worldwide, DTB 2018;56:3